AXIN2 (Axis Inhibition Protein 2) is a key regulatory component of the Wnt/β-catenin signaling pathway, which plays a critical role in embryonic development, tissue homeostasis, and cell proliferation. As a negative regulator, AXIN2 forms a destruction complex with other proteins (e.g., APC, GSK3β, and β-catenin) to promote the degradation of β-catenin, thereby inhibiting Wnt target gene transcription. However, Wnt pathway activation triggers AXIN2 upregulation through a negative feedback mechanism, making it both a target and modulator of Wnt signaling. Dysregulation of AXIN2 is implicated in various cancers (e.g., colorectal, hepatocellular carcinoma), fibrotic diseases, and developmental disorders.
AXIN2 antibodies are essential tools for studying its expression, localization, and function in biological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect AXIN2 protein levels in tissue samples, cell lines, or 3D organoid models. These antibodies help identify Wnt pathway activity, as elevated AXIN2 often correlates with hyperactive Wnt signaling. Researchers also utilize AXIN2 antibodies to explore its role as a potential biomarker for cancer prognosis, stem cell regulation, or tissue regeneration. Commercial AXIN2 antibodies are typically developed against specific epitopes, with validation across species (human, mouse, rat) and applications. However, variability in antibody specificity and sensitivity requires careful validation using controls like knockout models or siRNA-mediated knockdown to ensure reliability in experimental settings.